Get Your Personalized Supplement StackSupplement Stack Quiz

Cordycepsprime

Also known as: Cordyceps, Ophiocordyceps sinensis, Caterpillar fungus, Dong Chong Xia Cao, Cordycepsprime, Cordyceps sinensis

Overview

Cordyceps is a genus of parasitic fungi, with *Cordyceps sinensis* and *Ophiocordyceps sinensis* being the most researched species. Traditionally harvested from caterpillar larvae in the Himalayan region, it is now cultivated for supplement production. Cordycepsprime is a commercial preparation derived from these fungi. It's used primarily for respiratory health, renal dysfunction, immune support, anti-inflammatory effects, and exercise endurance. Key bioactive compounds include cordycepin, polysaccharides, and sterols. Research maturity is moderate, with multiple RCTs and meta-analyses, though many studies have methodological limitations. Evidence is promising but limited by small sample sizes, lack of placebo controls, and heterogeneity in preparations and outcomes.

Benefits

Cordyceps demonstrates several evidence-based benefits. Meta-analyses show that *Cordyceps sinensis* preparations improve lung function, exercise endurance, and quality of life in stable COPD patients (GOLD stages 2-3). Systematic reviews indicate it can improve clinical outcomes in patients with renal dysfunction, including acute kidney injury. Cordycepin, a key compound, exhibits anti-proliferative and anti-inflammatory effects by activating AMPK. In dialysis patients, *Ophiocordyceps sinensis* preparations significantly reduce C-reactive protein (CRP) levels, a marker of inflammation. Benefits are observed with intervention durations ranging from weeks to months, but longer-term effects require further study. Effect sizes for lung function and quality of life improvements are statistically significant but modest.

How it works

Cordyceps' mechanism of action involves the activation of AMP-activated protein kinase (AMPK), leading to anti-inflammatory and anti-proliferative effects. It modulates the immune response and reduces systemic inflammation markers like CRP. In the respiratory system, it improves lung function and exercise capacity. In the renal system, it supports renal function and reduces inflammation in kidney disease. Cordycepin and polysaccharides are bioactive constituents, and their bioavailability varies with preparation and formulation but are generally absorbed orally. The fungi interacts with the AMPK pathway and phosphorylation cascades involved in inflammation and cell proliferation.

Side effects

Cordyceps is generally considered safe, with no serious adverse events reported in meta-analyses. Common side effects are rare, with mild gastrointestinal discomfort reported in some studies. Allergic reactions are possible but uncommon. No significant rare adverse events have been documented in high-quality studies. Drug interactions are limited, but caution is advised when combined with immunosuppressants or anticoagulants due to theoretical interactions. Contraindications are not well defined, but caution is advised in pregnant or breastfeeding women due to a lack of data. Current evidence suggests it is safe in COPD and renal dysfunction patients, and dialysis patients have tolerated supplementation well.

Dosage

Effective doses of Cordyceps in studies range from 2 to 6 capsules daily, with diminishing returns above 6 capsules. There is no established maximum safe dose; doses above 6 capsules showed no additional benefit, and safety data are limited. It is administered orally daily, and benefits have been observed over weeks to months. Standardized extracts or formulations containing cordycepin and polysaccharides are preferred. Oral bioavailability is influenced by formulation, and co-administration with food has not been well studied. Studies used varying doses, commonly 2–6 capsules per day in dialysis patients.

FAQs

Is Cordycepsprime safe for long-term use?

Current evidence supports safety up to several months; long-term safety data are limited. Consult with a healthcare professional for extended use.

How soon can benefits be expected?

Improvements in inflammation and symptoms may appear within weeks; sustained use is generally recommended for optimal results.

Can Cordycepsprime replace conventional treatments?

It is an adjunctive therapy, not a replacement for standard care in COPD or renal disease. Continue with prescribed treatments.

Are there any known drug interactions?

Data are limited; caution is advised with immunosuppressants and anticoagulants. Consult with a healthcare provider before use.

Is Cordycepsprime effective for healthy individuals?

Most evidence focuses on disease populations; benefits in healthy subjects are not well established. More research is needed.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/39839641/ – This meta-analysis of 15 RCTs with 1,238 participants examined the effects of *Cordyceps sinensis* in stable COPD patients. The findings indicated significant improvements in lung function and symptoms, with no serious adverse events reported. However, the study acknowledged limitations such as the absence of placebo controls and moderate methodological quality.
https://pubmed.ncbi.nlm.nih.gov/31073318/ – This systematic review and meta-analysis investigated the use of *Cordyceps sinensis* for renal dysfunction, including acute kidney injury. The results showed significant therapeutic effects, supporting its adjunctive use in these conditions. The review noted a risk of bias and heterogeneity in study design, suggesting the need for further research.
https://www.mdpi.com/1420-3049/26/19/5886 – This systematic review focused on the biological effects of cordycepin, a key compound in Cordyceps. It highlighted the anti-inflammatory and anti-proliferative effects of cordycepin through AMPK activation. While the review provided clear evidence of biological activity, it noted that most studies were preclinical, and clinical translation requires further validation.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1477569/full – This meta-analysis examined the effects of *Ophiocordyceps sinensis* in dialysis patients, analyzing data from 19 studies. The findings showed a significant reduction in CRP levels, a marker of inflammation, with dose- and duration-dependent effects. The study acknowledged high heterogeneity and emphasized the need for standardized dosing.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1360997/full – This study provides a comprehensive review of Cordyceps' pharmacological properties and potential therapeutic applications. It highlights the fungi's immunomodulatory, anti-inflammatory, and antioxidant effects, supported by both in vitro and in vivo studies. The review emphasizes the need for further clinical trials to validate these findings and establish optimal dosing strategies.